Galiximab signals B-NHL cells and inhibits the activities of NF-κB-induced YY1- and snail-resistant factors: Mechanism of sensitization to apoptosis by chemoimmunotherapeutic drugs

Molecular Cancer Therapeutics

Volumn 11, Issue 3, 2012, Pages 572-581

  Martinez Paniagua, Melisa A ^a,b   Vega, Mario I ^a,c   Huerta Yepez, Sara ^a,d   Baritaki, Stavroula ^a   Vega, Gabriel G ^c   Hariharan, Kandasamy ^e   Bonavida, Benjamin ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^c Hospital de Oncología CMN Siglo XXI IMSS   (Mexico)

^d Unidad de Investigacion en Enfermedades Oncologicas Hospital Infantil de Mexico SSA   (Mexico)

^e BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; GALIXIMAB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR YY1;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; DRUG MECHANISM; DRUG SENSITIZATION; HUMAN; HUMAN CELL; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-X PROTEIN; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HUMANS; LYMPHOMA, B-CELL; NF-KAPPA B; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSCRIPTION FACTORS; YY1 TRANSCRIPTION FACTOR;

EID: 84859408851     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-11-0635     Document Type: Article

References (50)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007;18:581-92. (Pubitemid 46359643)
3. Morschhauser F, Dreyling M, Rohatiner A, Hagemeister F, Bischof DA. Rationale for consolidation to improve progression-free survival in patients with non-Hodgkin's lymphoma: a review of the evidence. Oncologist 2009;14 Suppl 2:17-29.
4. Pileri SA, Falini B. Mantle cell lymphoma. Haematologica 2009;94:1488-92.
5. Davis TA, Grillo-Lopez AJ, White CA, McLaughlin P, Czuczman MS, Link BK, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000;18:3135-43.
6. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825-33. (Pubitemid 28363048)
7. Golay J, Manganini M, Facchinetti V, Gramigna R, Broady R, Borleri G, et al. Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2. Haematologica 2003;88:1002-12. (Pubitemid 37151151)
8. Harjunpaa A, Junnikkala S, Meri S. Rituximab (anti-CD20) therapy of Bcell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scand J Immunol 2000;51:634-41. (Pubitemid 30353375)
9. Czuczman MS, Weaver R, Alkuzweny B, Berlfein J, Grillo-Lopez AJ. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 2004;22:4711-6.
10. Maloney DG, Smith B, Rose A. Rituximab: mechanism of action and resistance. Semin Oncol 2002;29:2-9. (Pubitemid 34171789)
11. June CH, Bluestone JA, Nadler LM, Thompson CB. The B7 and CD28 receptor families. Immunol Today 1994;15:321-31. (Pubitemid 24231747)
12. Schultze J, Nadler LM, Gribben JG. B7-mediated costimulation and the immune response. Blood Rev 1996;10:111-27. (Pubitemid 26234220)
13. Vyth-Dreese FA, Dellemijn TA, Majoor D, de JD. Localization in situ of the co-stimulatory molecules B7.1, B7.2, CD40 and their ligands in normal human lymphoid tissue. Eur J Immunol 1995;25:3023-9.
14. Dorfman DM, Schultze JL, Shahsafaei A, Michalak S, Gribben JG, Freeman GJ, et al. In vivo expression of B7-1 and B7-2 by follicular lymphoma cells can prevent induction of T-cell anergy but is insufficient to induce significant T-cell proliferation. Blood 1997;90:4297-306. (Pubitemid 27508435)
15. Munro JM, Freedman AS, Aster JC, Gribben JG, Lee NC, Rhynhart KK, et al. In vivo expression of the B7 costimulatory molecule by subsets of antigen-presenting cells and the malignant cells of Hodgkin's disease. Blood 1994;83:793-8.
16. Nozawa Y, Wakasa H, Abe M. Costimulatory molecules (CD80 and CD86) on Reed-Sternberg cells are associated with the proliferation of background T cells in Hodgkin's disease. Pathol Int 1998;48:10-4.
17. Tangri S, Dakappagari N, Estrellado A, Weng AP, Holmes E, Saville MW, et al. CD80 (B7.1) is expressed on both malignant B cells and tumor infiltrating T cells in Non-Hodgkin's lymphomas. ASH Annu Meet Abstr 2009;114:1953.
18. Plumas J, Chaperot L, Jacob MC, Molens JP, Giroux C, Sotto JJ, et al. Malignant B lymphocytes from non-Hodgkin's lymphoma induce allogeneic proliferative and cytotoxic T cell responses in primary mixed lymphocyte cultures: an important role of co-stimulatory molecules CD80 (B7-1) and CD86 (B7-2) in stimulation by tumor cells. Eur J Immunol 1995;25:3332-41.
19. Bolognesi A, Polito L, Tazzari PL, Lemoli RM, Lubelli C, Fogli M, et al. In vitro anti-tumour activity of anti-CD80 and anti-CD86 immunotoxins containing type 1 ribosome-inactivating proteins. Br J Haematol 2000;110:351-61. (Pubitemid 30646861)
20. Hariharan K, Anderson D, Leigh B. Therapeutic activity of IDEC-114 (anti-CD80) and rituximab (Rituxan) in B-cell lymphoma. Blood 2001;98:608a.
21. Suvas S, Singh V, Sahdev S, Vohra H, Agrewala JN. Distinct role of CD80 and CD86 in the regulation of the activation of B cell and B cell lymphoma. J Biol Chem 2002;277:7766-75. (Pubitemid 34968223)
22. Newman R, Alberts J, Anderson D, Carner K, Heard C, Norton F, et al. "Primatization" of recombinant antibodies for immunotherapy of human diseases: a macaque/human chimeric antibody against human CD4. Biotechnology (NY) 1992;10:1455-60.
23. Czuczman MS, Thall A, Witzig TE, Vose JM, Younes A, Emmanouilides C, et al. Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. J Clin Oncol 2005;23:4390-8. (Pubitemid 46207013)
24. Leonard JP, Friedberg JW, Younes A, Fisher D, Gordon LI, Moore J, et al. A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma. Ann Oncol 2007;18:1216-23. (Pubitemid 47244369)
25. Linsley PS, Clark EA, Ledbetter JA. T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1. Proc Natl Acad Sci U S A 1990;87:5031-5.
26. Jazirehi AR, Huerta-Yepez S, Cheng G, Bonavida B. Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis. Cancer Res 2005;65:264-76. (Pubitemid 40070818)
27. Vega MI, Huerta-Yepaz S, Garban H, Jazirehi A, Emmanouilides C, Bonavida B. Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: pivotal role of p38 MAPK in drug resistance. Oncogene 2004;23:3530-40. (Pubitemid 38658419)
28. Bonavida B. Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions. Oncogene 2007;26:3629-36. (Pubitemid 46842700)
29. Vega MI, Baritaki S, Huerta-Yepez S, Martinez-Paniagua MA, Bonavida B. A potential mechanism of rituximab-induced inhibition of tumor growth through its sensitization to tumor necrosis factor-related apoptosis-inducing ligand-expressing host cytotoxic cells. Leuk Lymphoma 2011;52:108-21.
30. Vega MI, Jazirehi AR, Huerta-Yepez S, Bonavida B. Rituximab-induced inhibition of YY1 and Bcl-xL expression in Ramos non-Hodgkin's lymphoma cell line via inhibition of NF-kappa B activity: role of YY1 and Bcl-xL in Fas resistance and chemoresistance, respectively. J Immunol 2005;175:2174-83. (Pubitemid 41113823)
31. Julien S, Puig I, Caretti E, Bonaventure J, Nelles L, van RF, et al. Activation of NF-kappaB by Akt upregulates Snail expression and induces epithelium mesenchyme transition. Oncogene 2007;26:7445-56. (Pubitemid 350158710)
32. Baritaki S, Chapman A, Yeung K, Spandidos DA, Palladino M, Bonavida B. Inhibition of epithelial to mesenchymal transition in metastatic prostate cancer cells by the novel proteasome inhibitor, NPI-0052: pivotal roles of Snail repression and RKIP induction. Oncogene 2009;28:3573-85.
33. Bonavida B, Baritaki S. Dual role of NO donors in the reversal of tumor cell resistance and EMT: downregulation of the NF-kappaB/Snail/YY1/RKIP circuitry. Nitric Oxide 2011;24:1-7.
34. Umezawa K, Chaicharoenpong C. Molecular design and biological activities of NF-kappaB inhibitors. Mol Cells 2002;14:163-7. (Pubitemid 41594968)
35. Vega MI, Huerta-Yepez S, Martinez-Paniagua M, Martinez-Miguel B, Hernandez-Pando R, Gonzalez-Bonilla CR, et al. Rituximab-mediated cell signaling and chemo/immuno-sensitization of drug-resistant B-NHL is independent of its Fc functions. Clin Cancer Res 2009;15:6582-94.
36. Berenbaum M. Toxicity of a furanocoumarin to armyworms: a case of biosynthetic escape from insect herbivores. Science 1978;201:532-4. (Pubitemid 8403991)
37. Jazirehi AR, Vega MI, Bonavida B. Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy. Cancer Res 2007;67:1270-81.
38. Kimura N, Miyakawa Y, Kohmura K, Umezawa K, Ikeda Y, Kizaki M. Targeting NF-kappaB and induction of apoptosis by novel NF-kappaB inhibitor dehydroxymethylepoxyquinomicin (DHMEQ) in Burkitt lymphoma cells. Leuk Res 2007;31:1529-35. (Pubitemid 47632787)
39. Vega MI, Martinez-Paniagua M, Jazirehi AR, Huerta-Yepez S, Umezawa K, Martinez-Maza O, et al. The NF-kappaB inhibitors (bortezomib and DHMEQ) sensitise rituximab-resistant AIDS-B-non-Hodgkin lymphoma to apoptosis by various chemotherapeutic drugs. Leuk Lymphoma 2008;49:1982-94.
40. Baritaki S, Katsman A, Chatterjee D, Yeung KC, Spandidos DA, Bonavida B. Regulation of tumor cell sensitivity to TRAIL-induced apoptosis by the metastatic suppressor Raf kinase inhibitor protein via Yin Yang 1 inhibition and death receptor 5 up-regulation. J Immunol 2007;179:5441-53.
41. Baritaki S, Yeung K, Palladino M, Berenson J, Bonavida B. Pivotal roles of snail inhibition and RKIP induction by the proteasome inhibitor NPI-0052 in tumor cell chemoimmunosensitization. Cancer Res 2009;69:8376-85.
42. Palmer MB, Majumder P, Cooper JC, Yoon H, Wade PA, Boss JM. Yin yang 1 regulates the expression of snail through a distal enhancer. Mol Cancer Res 2009;7:221-9.
43. Backing C. Biogen Idec Initiates Phase III Trial Of Galiximab For Follicular Non-Hodgkin's Lymphoma. Medical News Today. MediLexicon, Intl., 29 Jan. 2007. Web. 13 Jan. 2012. http://www.medicalnewstoday.com/releases/61815.php
44. Jenkins MK, Taylor PS, Norton SD, Urdahl KB. CD28 delivers a costimulatory signal involved in antigen-specific IL-2 production by human T cells. J Immunol 1991;147:2461-6.
45. de Boer M, Parren P, Dove J, Ossendorp F, van der Horst G, Reeder J. Functional characterization of a novel anti-B7 monoclonal antibody. Eur J Immunol 1992;22:3071-5.
46. Antonio-Andres G, Pelayo R, Dorantes-Acosta E, Lopez-Martinez B, Tirado-Rodriguez B, Diaz-Elizondo G, et al. High expression of transcription factor Yin Yang 1 and multidrug resistance protein in early B-Cell precursors in childhood Acute Lymphoblastic Leukemia. ASH Annu Meet Abstr 2009;114:4695.
47. Vega S, Morales AV, Ocana OH, Valdes F, Fabregat I, Nieto MA. Snail blocks the cell cycle and confers resistance to cell death. Genes Dev 2004;18:1131-43. (Pubitemid 38669034)
48. Ramljak D, Coticchia CM, Nishanian TG, Saji M, Ringel MD, Conzen SD, et al. Epidermal growth factor inhibition of c-Myc-mediated apoptosis through Akt and Erk involves Bcl-xL upregulation in mammary epithelial cells. Exp Cell Res 2003;287:397-410. (Pubitemid 37323851)
49. Yook JI, Li XY, Ota I, Fearon ER, Weiss SJ. Wnt-dependent regulation of the E-cadherin repressor snail. J Biol Chem 2005;280:11740-8. (Pubitemid 40418488)
50. Miles RR, Cairo MS, Satwani P, Zwick DL, Lones MA, Sposto R, et al. Immunophenotypic identification of possible therapeutic targets in pediatric non-Hodgkin lymphomas: a children's oncology group report. Br J Haematol 2007;138:506-12. (Pubitemid 47063039)